{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:17:01Z","timestamp":1790810221162,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The short-term mortality rate of hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) is relatively high, and the optimal therapeutic method for HBV-ACLF is still controversial. This study aimed to investigate the effects of different therapeutic methods on 90-day prognosis of HBV-ACLF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, Embase, and Cochrane Library were searched from their inception date up to February 2, 2023. RCTs or cohort studies related to the treatment of HBV-ACLF with different therapies were identified. Therapeutic methods focused on plasma exchange (PE), mesenchymal stem cell (MSC), granulocyte colony-stimulating factor (G-CSF), glucocorticoid (GC), double plasma molecular absorption system (DPMAS), and nucleos(t)ide analogues. The primary outcome was the 90-day survival rate. The results for binary variables were calculated using odds ratio (OR), with a corresponding 95% confidence interval (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 16 studies were included in this study, which contained the therapeutic methods of PE, GC, G-CSF, MSC, DPMAS\u2005+\u2005PE, MSC\u2005+\u2005PE. Compared to nucleos(t)ide analogues, treatment with MSC\u2005+\u2005PE, DPMAS\u2005+\u2005PE, G-CSF, MSC and PE increased the odds of 90-day survival rate (OR\u2005=\u20054.58, 95% CI: 1.95\u201310.75; OR\u2005=\u20052.95, 95% CI: 1.07\u20138.12; OR\u2005=\u20052.32, 95% CI: 1.15\u20134.69; OR\u2005=\u20052.36, 95% CI: 1.14\u20134.91; OR\u2005=\u20051.91, 95% CI: 1.42\u20132.77), respectively. The odds of the 90-day survival rate after being treated by MSC\u2005+\u2005PE were superior to PE (OR\u2005=\u20052.40, 95% CI: 1.05\u20135.51) and GC treatment (OR\u2005=\u20052.86, 95% CI: 1.01\u20138.09). MSC\u2005+\u2005PE exhibited the highest likelihood (0.92) of being the optimal therapeutic method in improving the prognosis of patients with HBV-ACLF. For single-drug regimens, G-CSF (0.58) ranks the highest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This meta-analysis showed that MSC\u2005+\u2005PE was the most effective therapy in improving the 90-day prognosis, and G-CSF was the potential optimal monotherapy in improving the 90-day prognosis of HBV-ACLF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046388","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T04:00:30Z","timestamp":1766203230000},"page":"e46388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effects of different therapeutic methods on the 90-day prognosis of patients with HBV-ACLF: A systematic review and network meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Yin","family":"Hua","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Qingdao Clinical Medical College Affiliated to Nanjing Medical University, Qingdao Municipal Hospital, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qingdao Sixth People\u2019s Hospital, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Wuxi Clinical Medical College Affiliated to Nanjing Medical University, Wuxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shousheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Qingdao Clinical Medical College Affiliated to Nanjing Medical University, Qingdao Municipal Hospital, Qingdao, China"},{"name":"Department of Infectious Disease, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260522","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol Int"},{"key":"R2-20260522","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3350\/cmh.2022.0103","article-title":"Acute -on- Chronic liver failure - terminology, mechanisms and management.","volume":"29","author":"Br","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R3-20260522","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/TP.0000000000003550","article-title":"Liver transplantation in acute-on-chronic liver failure.","volume":"105","author":"Karvellas","year":"2021","journal-title":"Transplantation"},{"key":"R4-20260522","first-page":"433","article-title":"Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis b liver failure.","volume":"11","author":"Wu","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"R5-20260522","doi-asserted-by":"crossref","first-page":"779744","DOI":"10.3389\/fmed.2021.779744","article-title":"Plasma exchange-based non-bioartificial liver support system improves the short-term outcomes of patients with hepatitis b virus-associated acute-on-chronic liver failure: a multicenter prospective cohort study.","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med"},{"key":"R6-20260522","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1055\/s-0041-1730971","article-title":"Plasma exchange in acute and acute on chronic liver failure.","volume":"41","author":"Maiwall","year":"2021","journal-title":"Semin Liver Dis"},{"key":"R7-20260522","doi-asserted-by":"crossref","first-page":"300060520932053","DOI":"10.1177\/0300060520932053","article-title":"Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure.","volume":"48","author":"Guo","year":"2020","journal-title":"J Int Med Res"},{"key":"R8-20260522","doi-asserted-by":"crossref","first-page":"e20604","DOI":"10.1097\/MD.0000000000020604","article-title":"Glucocorticoid versus traditional therapy for hepatitis B virus-related acute-on-chronic liver failure: a systematic review and meta-analysis.","volume":"99","author":"Gao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R9-20260522","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1574888X15666200101124317","article-title":"A brief analysis of mesenchymal stem cells as biological drugs for the treatment of Acute-on-Chronic Liver Failure (ACLF): safety and potency.","volume":"15","author":"Feng","year":"2020","journal-title":"Curr Stem Cell Res Ther"},{"key":"R10-20260522","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jhep.2021.07.033","article-title":"Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study).","volume":"75","author":"Engelmann","year":"2021","journal-title":"J Hepatol"},{"key":"R11-20260522","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","article-title":"Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.","volume":"21","author":"Li","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R12-20260522","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons.","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"R13-20260522","doi-asserted-by":"crossref","first-page":"e9728","DOI":"10.1590\/1414-431x20209728","article-title":"A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure.","volume":"53","author":"Zhu","year":"2020","journal-title":"Brazilian J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas"},{"key":"R14-20260522","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12015-016-9683-3","article-title":"Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and entecavir: a 24-month prospective study.","volume":"12","author":"Li","year":"2016","journal-title":"Stem Cell Rev Reports"},{"key":"R15-20260522","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s12072-015-9667-4","article-title":"The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure.","volume":"10","author":"Yue-Meng","year":"2016","journal-title":"Hepatol Int"},{"key":"R16-20260522","doi-asserted-by":"crossref","first-page":"E434","DOI":"10.1111\/aor.13710","article-title":"Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.","volume":"44","author":"Liu","year":"2020","journal-title":"Artif Organs"},{"issue":"8 Pt 1","key":"R17-20260522","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1440-1746.2008.05484.x","article-title":"Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment.","volume":"23","author":"Yu","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R18-20260522","doi-asserted-by":"crossref","first-page":"4130757","DOI":"10.1155\/2019\/4130757","article-title":"Combination treatments of plasma exchange and umbilical cord-derived mesenchymal stem cell transplantation for patients with hepatitis B virus-related acute-on-chronic liver failure: a clinical trial in China.","volume":"2019","author":"Xu","year":"2019","journal-title":"Stem Cells Int"},{"key":"R19-20260522","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1097\/MD.0000000000000338","article-title":"Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience.","volume":"93","author":"Qin","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R20-20260522","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s40001-022-00891-w","article-title":"Early prediction model for prognosis of patients with hepatitis-B-virus-related acute-on-chronic liver failure received glucocorticoid therapy.","volume":"27","author":"Gao","year":"2022","journal-title":"Eur J Med Res"},{"key":"R21-20260522","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jgh.12454","article-title":"Dexamethasone in outcome of patients with hepatitis B virus-related acute-on-chronic liver failure.","volume":"29","author":"Chen","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R22-20260522","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12916-020-01814-4","article-title":"The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial.","volume":"18","author":"Jia","year":"2020","journal-title":"BMC Med"},{"key":"R23-20260522","doi-asserted-by":"crossref","first-page":"885829","DOI":"10.3389\/fimmu.2022.885829","article-title":"Granulocyte colony-stimulating factor accelerates the recovery of hepatitis B virus-related acute-on-chronic liver failure by promoting M2-Like transition of monocytes.","volume":"13","author":"Tong","year":"2022","journal-title":"Front Immunol"},{"key":"R24-20260522","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3748\/wjg.v19.i7.1104","article-title":"Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure.","volume":"19","author":"Duan","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R25-20260522","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.29189","article-title":"Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.","volume":"66","author":"Lin","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"key":"R26-20260522","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5966\/sctm.2012-0034","article-title":"Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients.","volume":"1","author":"Shi","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"R27-20260522","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/MEG.0000000000001156","article-title":"Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis.","volume":"30","author":"Chen","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R28-20260522","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3727\/096368915X686841","article-title":"Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy.","volume":"24","author":"Ding","year":"2015","journal-title":"Cell Transplant"},{"key":"R29-20260522","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2174\/1574888X18666221214123844","article-title":"Mesenchymal Stem Cell Transplantation for hepatitis B virus-related acute-on-chronic liver failure:a systematic review and meta-analysis.","volume":"18","author":"Cheng","year":"2023","journal-title":"Curr Stem Cell Res Ther"},{"key":"R30-20260522","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s13287-021-02544-x","article-title":"The impact of recipient age on the effects of umbilical cord mesenchymal stem cells on HBV-related acute-on-chronic liver failure and liver cirrhosis.","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"R31-20260522","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/jhep.2000.9124","article-title":"Liver from bone marrow in humans.","volume":"32","author":"Theise","year":"2000","journal-title":"Hepatology (Baltimore, Md)"},{"key":"R32-20260522","doi-asserted-by":"crossref","first-page":"1096402","DOI":"10.3389\/fimmu.2022.1096402","article-title":"Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R33-20260522","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbrc.2007.05.150","article-title":"Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells.","volume":"363","author":"Parekkadan","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R34-20260522","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-0042-1755328","article-title":"Mesenchymal stem cell transplantation in liver diseases.","volume":"42","author":"Nevens","year":"2022","journal-title":"Semin Liver Dis"},{"key":"R35-20260522","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1665-2681(19)30757-4","article-title":"Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis.","volume":"14","author":"Chavez-Tapia","year":"2015","journal-title":"Ann Hepatol"},{"key":"R36-20260522","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5144\/0256-4947.2021.383","article-title":"Effectiveness of granulocyte colony-stimulating factor for patients with acute-on-chronic liver failure: a meta-analysis.","volume":"41","author":"Huang","year":"2021","journal-title":"Ann Saudi Med"},{"key":"R37-20260522","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3748\/wjg.v26.i2.219","article-title":"Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review.","volume":"26","author":"Tan","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R38-20260522","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13613-020-00795-0","article-title":"Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis.","volume":"11","author":"Ocskay","year":"2021","journal-title":"Ann Intensive Care"},{"key":"R39-20260522","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jca.21535","article-title":"Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: a prospective study.","volume":"32","author":"Wan","year":"2017","journal-title":"J Clin Apher"},{"key":"R40-20260522","doi-asserted-by":"crossref","first-page":"3139929","DOI":"10.1155\/2022\/3139929","article-title":"The clinical efficacy of double plasma molecular absorption system combined with plasma exchange in the treatment of acute-on-chronic liver failure: a systematic review and meta-analysis.","volume":"2022","author":"Bai","year":"2022","journal-title":"J Healthcare Eng"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:00:35Z","timestamp":1779433235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":40,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046388","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"2024-05-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}